FDA Accepts Merck New Drug Application for Sugammadex Sodium Injection

Share on Facebook
Merck's new drug application resubmission for sugammadex sodium injection has been accepted for review by the FDA.

Neuromuscular blockade, which is used by anesthesiologists to relax muscles during surgery, is revered by the sugammadex sodium injection. Upon approval, this substance would be one of the first medicines of its kind to be used in the U.S. surgical setting.

The FDA previously rejected the NDA in 2008 and requested more data on allergic reactions and bleeding events. The application has now been deemed complete for review.

More Articles on Anesthesia:

Novitas Expected to Revise Limits to Anesthesia Coverage
6 ASC Characteristics That Matter to Anesthesiologists
Children's National Medical Center Names Joint Chief Medical Officers








© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

New from Becker's ASC Review

Dr. Howard Zucker to Take Over New York Health Commissioner Duties, Following Dr. Nirav Shah's Departure

Read Now